Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1997-09-04
1999-12-21
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
424401, 514 75, 514 78, 514844, 514863, 514880, 4352402, 4352403, A61K 9127
Patent
active
060045795
DESCRIPTION:
BRIEF SUMMARY
FIELD OF INVENTION
This invention relates to compositions of matter which are effective in inhibiting apoptotic cell death. More specifically, it relates to compositions of phospholipids (PA, PI, LPA, LPI and LPC) the mixture of which exhibits anti-apoptotic activity.
BACKGROUND OF THE INVENTION
Apoptosis is a normal physiologic process that leads to individual cell death. This process of programmed cell death is involved in a variety of normal and pathogenic biological events and can be induced by a number of unrelated stimuli. Changes in the biological regulation of apoptosis also occur during aging and are responsible for many of the conditions and diseases related to aging.
Recent studies of apoptosis have implied that a common metabolic pathway leading to apoptosis may be initiated by a wide variety of signals, including hormones, serum growth factor deprivation, chemotherapeutic agents, ionizing radiation, and infection by human imnmunodeficiency virus (HIV). Wyllie (1980) Nature 284:555-556; Kanter et al. (1984) Biochem. Biophys. Res. Commun. 118:392-399; Duke and Cohen (1986) Lymphokine Res. 5:289-299; Tomei et al. (1988) Biochem. Biophys. Res. Commun. 155:324-331; Kruman et al. (1991) J. Cell. Physiol. 148:267-273; Ameisen and Capron (1991) Immunol. Today 12:102-105; and Sheppard and Ascher (1992) J. AIDS 5:143-147. Agents that affect the biological control of apoptosis thus have therapeutic utility in numerous clinical indications.
Apoptotic cell death is characterized by cellular shrinkage. chromatin condensation, cytoplasmic blebbing, increased membrane permeability and internucleosomal DNA cleavage. Gerschenson et al. (1992) FASEB J. 6:2450-2455; and Cohen and Duke (1992) Ann. Rev. Immunol. 10:267-293.
A variety of food supplements containing, in part, partially processed plant extracts have been used to ameliorate the gastrointestinal disorders that often accompany chemotherapy, radiation and AIDS. The supplements generally contain carbohydrates, fat and plant protein hydrolysates. See, e.g., Tomei and Cope et al. in Apoptosis The Molecular Basis of Cell Death (1991) Cold Spring Harbor Laboratory Press.
Several proteinase inhibitors derived from plant extracts have anticarcinogenic activity. Troll et al. (1987) Adv. Cancer Res. 49:265-283. The Bowman-Birk inhibitors are the best described of these inhibitors. Birk (1985) Int. J. Pep. Pro. Res. 25:113-131. Bowman-Birk inhibitors are described as a family of disulfide bonded proteins with a molecular weight of about 8 kD which suppress cellular transformation. Chou et al. (1974) Proc. Natl. Acad. Sci. USA 71:1748-1752; Yavelow et al. (1985) Proc. Natl. Acad. Sci. USA 82:5395-5399; and Yavelow et al. (1983) Cancer Res. (Suppl.) 43:2454s-2459s. Crude soybean extracts containing Bowman-Birk inhibitors have been described. Kennedy et al. U.S. Pat. No. 4,793,996; PCT publication No. WO 94/20121; and Kennedy, A. R. (1994) Cancer Res. (Suppl) 54: 1999s-2005s. Bowman-Birk inhibitors have also been described immunologically. WO 90/03574; and U.S. Pat. Nos. 4,959,310; and 5,053,327. Bowman-Birk inhibitors have also been found to have activity in degranulation of macrophages. Japanese Patent No. 63051335.
Phospholipids are a class of amphipathic phosphorous-containing lipids which are essential constituents of biological membranes. Various phospholipid preparations have been used for cooking, drug delivery (liposomes), slow release delivery systems, carrier media for hydrophobic drugs, gene transfer and replacement therapy, sunscreens, emulsions, anti-foaming agents, replacement of damaged or absent pulmonary surfactants, detergents and membrane stabilization.
Phosphatidic acid (PA), phosphatidylinositol (PI), lysophosphatidic acid (LPA), lysophosphatidylinositol (LPI), and lysophosphatidylcholine (LPC) are found in a variety of plant and animal products. LPA is found in a variety of plant and animal products and has been reported to have a variety of physiological activities including mitogenesis, growth factor and to be an anmi-wrinkle agent. U.S. P
REFERENCES:
Aussel et al., "Human alpha-fetoprotein-fatty acid interaction" Biochem. Biophys. Res. Comm. (1983) 115:38-45.
Banaszak et al., "Lipid-binding proteins: A family of fatty acid and retinoid transport proteins" Advances in Protein Chemistry (1994) 45:89-151.
Bass, "Cellular binding proteins for fatty acids and retinoids: similar or specialize functions?" Mol. Cell. Biochem. (1993) 123:191-202.
Belzer et al., "Principles of solid-organ preservation by cold storage" Transplantation (1988) 45:673-676.
Buerke et al., "Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion" Proc. Natl. Acad. Sci. USA (1995) 92:8031-8035.
Burnham, "Polymers for delivering peptides and proteins" Am. J. Hosp. Pharm. (1994) 51:210-218.
Collins et al., "New organ preservation solutions" Kidney International (1992) 42 (Suppl. 38):S-197-S-202.
Collins et al., Heart preservation solution containing polyethyleneglycol: an immunosuppresive effect? The Lancet (1991) 338:890.
Cooper, ed., The Transplantation and Replacement of Thoracic Organs, Kluwer Academic Publishers, Dordrecht (1997). A title page and table of contents are included herewith.
Delgado et al., "The uses and properties of PEG-linked proteins" Crit. Rev. Ther. Drug. Carrier Sys. (1992) 9:249-304.
Donovan et al., "The cellular retinoic acid binding proteins" J. Steroid Biochem. Mol. Biol. (1995) 53:459-465.
Elorza et al., "Comparison of particle size and encapsulation parameters of three liposomal preparations" J. Microencapsulation (1993) 10:237-248.
Fex et al., "Studies of the spontaneous transfer of retinol from the retinol: retinol-binding protein complex to unilamellar liposomes" Biochim. Biophys. Acta (1987) 901:255-264.
Flower, "The lipocalin protein family:structure and function" Biochem. J. (1996) 318:1-14.
Fordyce et al., "Studies on reactions relating to carbohydrates and polysaccharides. LVI. The synthesis of the higher polyoxyethylene glycols" J. Am. Chem. Soc. (1939) 61:1905-1910.
Fox, "Reperfusion injury: laboratory phenomenon or clinical reality?" Cardiovasc. Res. (1992) 26:656-659.
Friede et al., "Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered in liposomes" Vaccine (1994) 12:791-797.
Geisow et al. "Structures and functions of a supergene family of calcium and phospholipid binding proteins" Prog. Clin. Biol. Res. (1990) 349:111-121.
Ghosh et al., "Targeting of liposomes to hepatocytes" Liver Diseases, Targeted Diagnosis and Therapy Using Specific Receptors and Ligands (1991) Wu et al., ed., Marcel Dekker, New York, pp. 87-103.
Glatz et al., "Intracellular transport of lipids" Mol. Cell. Biochem. (1989) 88:37-44.
Gossett et al., "Acyl-CoA binding proteins: Multiplicity and function" Lipids (1996) 31:895-918.
Gottlieb et al., "Reperfusion injury induces apoptosis in rabbit cardiomyocytes" J. Clin. Invest. (1994) 94:1621-1628.
Gregoriadis, ed., Liposomes as Drug Carriers: Recent Trends and Progress (1988) John Wiley & Sons, New York. A title page and table of contents are included herewith.
Gregoriadis, Liposome Technology 2nd Edition Volume I: Liposome Preparation and Related Techniques (1993) CRC Press, Boca Raton. A title page and table of contents are included herewith.
Hamilton et al., "Locations of the three primary binding sites for long-chain fatty acids on bovine serum albumin" Proc. Natl. Acad. Sci. USA (1991) 88:2051-2054.
Ishihara, "Preparation of asialofetuin-labeled liposomes with encapsulated human interferon-.gamma. and their uptake by isolated rat hepatocytes" Pharm. Res. (1990) 7:542-546.
Itasaka et al., "Modification of rejection of polyethylene glycol in small bowel transplantation" Transplantation (1994) 57:645-648.
Itoh et al., "DNA fragmentation of human infarcted myocardial cells demonstrated by the nick end labeling method and DNA agarose gel electrophoresis" Am. J. Pathol. (1995) 146:1325-1331.
Karmazyn, "Ischemic and reperfusion injury in the heart. Cellular mec
Barr Philip J.
Bathurst Ian C.
Foehr Matthew W.
Goddard John G.
Tomei L. David
Kishore Gollamudi S.
LXR Biotechnology Inc.
LandOfFree
Compositions which inhibit apoptosis, methods of making the comp does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions which inhibit apoptosis, methods of making the comp, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions which inhibit apoptosis, methods of making the comp will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-502376